School of Medical Sciences and Charles Perkins Centre, The University of Sydney, New South Wales 2006, Australia.
Nat Rev Drug Discov. 2017 Jun;16(6):424-440. doi: 10.1038/nrd.2016.266. Epub 2017 Mar 10.
Kinome-wide profiling platforms have comprehensively identified the relevant kinases that are targeted by numerous protein kinase inhibitors. However, recent projects have begun to discover non-kinase targets of kinase inhibitors. These non-kinase targets can contribute to the desired or undesired activities of inhibitors, or act as silent bystanders. As a full awareness of a drug's mechanism of action is crucial for the interpretation of results and for successful preclinical and clinical drug development, these discoveries highlight the importance of understanding the pharmacology of kinase inhibitors beyond the kinome. In this Review, I discuss kinase inhibitors for which non-kinase targets have been identified and the application of emerging techniques to validate drug-target engagement in intact cells.
激酶组学分析平台全面鉴定了多种蛋白激酶抑制剂的作用靶点激酶。然而,最近的研究项目开始发现激酶抑制剂的非激酶作用靶点。这些非激酶靶点可能有助于解释抑制剂的预期或非预期活性,或者作为沉默的旁观者。由于全面了解药物的作用机制对于解释结果以及成功进行临床前和临床药物开发至关重要,因此这些发现强调了在激酶组学之外理解激酶抑制剂药理学的重要性。在这篇综述中,我讨论了已鉴定出非激酶靶点的激酶抑制剂,以及新兴技术在验证完整细胞中药物靶标结合的应用。